Changelog — 2026-02-09
2026-02-09
E
ECOR
electroCore, Inc.
Enrollment 2→3 (50%) — NA
NCT04935697
• Na • Enrollment 2→3 (+50%)
MEDIUM
2026-02-09
T
TELA
TELA Bio, Inc.
Enrollment 133→173 (30%) — NA
NCT07070115
• Na • Enrollment 133→173 (+30%)
MEDIUM
2026-02-09
O
ONON
On Holding AG
Enrollment 150→74 (-51%) — NA
NCT04064463
• Na • Enrollment 150→74 (-51%)
MEDIUM
2026-02-09
O
OLMA
Olema Pharmaceuticals, Inc.
Locations updated — PHASE3
NCT07085767
• Phase 3
MEDIUM
2026-02-09
GILD
GILEAD SCIENCES, INC.
Enrollment 45→36 (-20%) — PHASE1
NCT06071767
• Phase 1 • Enrollment 45→36 (-20%)
MEDIUM
2026-02-09
VTRS
Viatris Inc
Status: RECRUITING → ACTIVE_NOT_RECRUITING — PHASE3
NCT05672576
• Phase 3 • Status: Recruiting → Active, not recruiting
MEDIUM
2026-02-09
VTRS
Viatris Inc
Enrollment 420→451 (7%) — PHASE3
NCT05672576
• Phase 3 • Enrollment 420→451 (+7%)
MEDIUM
2026-02-09
G
GSCCF
ioneer Ltd
Enrollment 1372→2350 (71%)
NCT05117788
• Enrollment 1372→2350 (+71%)
MEDIUM
2026-02-09
N
NRC
NATIONAL RESEARCH CORP
Enrollment 60→58 (-3%) — PHASE1
NCT06705530
• Phase 1 • Enrollment 60→58 (-3%)
MEDIUM
2026-02-09
MFG
MIZUHO FINANCIAL GROUP INC
Primary endpoint added: Rate of permanent aneurysm occlusions
MEDIUM
2026-02-09
O
ONON
On Holding AG
Primary endpoint removed: TB treatment completion rates after release from prison using a visual analog scale (VAS) — NA
NCT03089983
• Na
MEDIUM
2026-02-09
O
ONON
On Holding AG
Enrollment 1702→316 (-81%) — NA
NCT03089983
• Na • Enrollment 1702→316 (-81%)
MEDIUM
2026-02-09
MDT
Medtronic plc
Enrollment 515→516 (0%) — NA
NCT04075500
• Na • Enrollment 515→516 (+0%)
MEDIUM
2026-02-09
S
STOK
Stoke Therapeutics, Inc.
Enrollment 150→170 (13%) — PHASE3
NCT06872125
• Phase 3 • Enrollment 150→170 (+13%)
MEDIUM
2026-02-09
S
SO
SOUTHERN CO
Enrollment 360→131 (-64%) — NA
NCT03904186
• Na • Enrollment 360→131 (-64%)
MEDIUM
2026-02-09
AZN
ASTRAZENECA PLC
Enrollment 103→104 (1%) — PHASE1
NCT06132841
• Phase 1 • Enrollment 103→104 (+1%)
MEDIUM